LLY

719.77

-0.71%↓

JNJ

149.05

+1.61%↑

UNH

261.46

-16.63%↓

ABBV

177.76

-1.78%↓

ABT

132.2

+2.19%↑

LLY

719.77

-0.71%↓

JNJ

149.05

+1.61%↑

UNH

261.46

-16.63%↓

ABBV

177.76

-1.78%↓

ABT

132.2

+2.19%↑

LLY

719.77

-0.71%↓

JNJ

149.05

+1.61%↑

UNH

261.46

-16.63%↓

ABBV

177.76

-1.78%↓

ABT

132.2

+2.19%↑

LLY

719.77

-0.71%↓

JNJ

149.05

+1.61%↑

UNH

261.46

-16.63%↓

ABBV

177.76

-1.78%↓

ABT

132.2

+2.19%↑

LLY

719.77

-0.71%↓

JNJ

149.05

+1.61%↑

UNH

261.46

-16.63%↓

ABBV

177.76

-1.78%↓

ABT

132.2

+2.19%↑

Search

Novo Nordisk A-S

Open

SectorHealthcare

65.49 1.21

Overview

Share price change

24h

Current

Min

64.09

Max

65.79

Key metrics

By Trading Economics

Income

804M

29B

Sales

-7.6B

78B

P/E

Sector Avg

19.19

56.602

EPS

6.53

Dividend yield

2.39

Profit margin

37.182

Employees

76,302

EBITDA

5.9B

46B

Recommendations

By TipRanks

Recommendations

Neutral

12 Months Forecast

+42.97% upside

Dividends

By Dow Jones

Dividend yield

Sector Avg

2.39%

2.45%

Market Stats

By TradingEconomics

Market Cap

29B

295B

Previous open

64.28

Previous close

65.49

News Sentiment

By Acuity

18%

82%

34 / 382 Healthcare

Technical Score

By Trading Central

Confidence

Weak Bearish Evidence

Novo Nordisk A-S Chart

Past performance is not a reliable indicator of future results.

Related News

12 May 2025, 09:36 UTC

Major Market Movers

Global Pharma Stocks Fall as Trump Plans to Cut Drug Prices

7 May 2025, 11:29 UTC

Top News
Earnings
Major Market Movers

Novo Nordisk Investors Breathe Sigh of Relief Despite Guidance Hit From Copycat Drugs -- 2nd Update

7 May 2025, 07:05 UTC

Earnings

Novo Nordisk Cuts Guidance as Copycat Versions of Ozempic Hit Sales -- Update

7 May 2025, 06:19 UTC

Earnings

Novo Nordisk Cuts Guidance as Copycat Versions of Ozempic Hit Sales

12 May 2025, 22:14 UTC

Top News

Drugmakers Spared Worst-Case Drug Pricing Scenario for Now -- 2nd Update

12 May 2025, 18:45 UTC

Top News

Drugmakers Spared Worst-Case Drug Pricing Scenario for Now -- Update

12 May 2025, 12:07 UTC

Market Talk

Trump's Drug Price Cap Plan Is 'Alarming' for Pharma Sector -- Market Talk

12 May 2025, 07:20 UTC

Market Talk

Pharma Shares Face Risks From Trump's Pricing Plans -- Market Talk

7 May 2025, 15:13 UTC

Earnings

These Stocks Are Moving the Most Today: Super Micro, AMD, Marvell, Disney, Uber, Arista, Sarepta, Charles River, and More -- Barrons.com

7 May 2025, 13:56 UTC

Earnings

Novo Nordisk Stock Jumps After Earnings. Compounding Market's Growth Took it By Surprise -- Barrons.com

7 May 2025, 13:45 UTC

Earnings

These Stocks Are Moving the Most Today: Super Micro, AMD, Marvell, Disney, Uber, Nordisk, Sarepta, EA, Upstart, and More -- Barrons.com

7 May 2025, 11:25 UTC

Earnings

These Stocks Are Moving the Most Today: Super Micro, AMD, Disney, Uber, Novo Nordisk, Sarepta, EA, Tesla, and More -- Barrons.com

7 May 2025, 11:18 UTC

Earnings

Novo Nordisk Stock Jumps After Earnings. It Cuts Guidance as Weight-Loss Drug Sales Slow. -- Barrons.com

7 May 2025, 09:55 UTC

Earnings

These Stocks Are Moving the Most Today: Super Micro, AMD, Novo Nordisk, Sarepta, EA, Rivian, Disney, and More -- Barrons.com

7 May 2025, 09:36 UTC

Earnings

These Stocks Are Moving the Most Today: Super Micro, AMD, Novo Nordisk, Sarepta, EA, Rivian, Tesla, and More -- Barrons.com

7 May 2025, 09:04 UTC

Earnings
Hot Stocks

Stocks to Watch Wednesday: Disney, Uber, Super Micro -- WSJ

7 May 2025, 08:10 UTC

Market Talk

Novo Nordisk Cuts Guidance Slightly More Than Expected -- Market Talk

7 May 2025, 08:08 UTC

Market Talk

Novo Nordisk's Downgraded Guidance Assumes Large Wegovy Uplift in 2H -- Market Talk

7 May 2025, 07:11 UTC

Market Talk
Earnings

Novo Nordisk Shares Seen Under Pressure After Downgrade -- Market Talk

7 May 2025, 05:39 UTC

Earnings

Novo Nordisk: Sales Outlook Assumes Reduction in Patients on Compounded GLP-1 Treatments During 2H25

7 May 2025, 05:38 UTC

Earnings

Novo Nordisk 1Q Wegovy Drug Sales Rose 83% To DKK17.36B, Consensus Saw DKK18.5B

7 May 2025, 05:37 UTC

Earnings

Novo Nordisk 1Q Ozempic Drug Sales Rose 15% To DKK32.72B, Consensus Saw DKK32.01B

7 May 2025, 05:36 UTC

Earnings

Novo Nordisk 1Q Gross Margin 83.5% Vs 84.8%

7 May 2025, 05:35 UTC

Earnings

Novo Nordisk: Focused on Preventing Unlawful Compounding and Further Expanding Access in US

7 May 2025, 05:34 UTC

Earnings

Novo Nordisk: US Sales of Branded GLP-1 Treatments Impacted By Compounded Versions

7 May 2025, 05:34 UTC

Earnings

Novo Nordisk: Sales Outlook Reflects Lower-Than-Planned Penetration of Branded GLP-1 Treatments in US

7 May 2025, 05:33 UTC

Earnings

Novo Nordisk: Had Seen 2025 Op Profit Growth of 19%-27% in Constant Currency

7 May 2025, 05:33 UTC

Earnings

Novo Nordisk: Had Seen 2025 Sales Growth of 16%-24% in Constant Currency

7 May 2025, 05:33 UTC

Earnings

Novo Nordisk Now Sees 2025 Op Profit Growth of 16%-24% in Constant Currency

7 May 2025, 05:32 UTC

Earnings

Novo Nordisk Now Sees 2025 Sales Growth of 13%-21% in Constant Currency

Peer Comparison

Price change

Novo Nordisk A-S Forecast

Price Target

By TipRanks

42.97% upside

12 Months Forecast

Average 92.09 USD  42.97%

High 136.527 USD

Low 61 USD

Based on 9 Wall Street analysts offering 12 month price targets forNovo Nordisk A-S - Dist in the last 3 months.

Rating Consensus

By TipRanks

Neutral

9 ratings

3

Buy

5

Hold

1

Sell

Technical Score

By Trading Central

62.63 / 69.23Support & Resistance

Short Term

Weak Bearish Evidence

Intermediate Term

Bullish Evidence

Long Term

Bearish Evidence

Sentiment

By Acuity

34 / 382 Healthcare

News Sentiment

Very Strong Bullish Evidence

Volatility

Below average

News Volume (RCV)

Above average

Financials

Selling and administration expenses

Operating expenses

Pre-tax profit

Sales

Cost of sales

Gross profit on sales

Interest expense on debt

EBITDA

Operating profit

$

About Novo Nordisk A-S

Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease. The Diabetes and Obesity care segment provides products for diabetes, obesity, cardiovascular, and other emerging therapy areas. The Rare Disease segment offers products in the areas of rare blood disorders, rare endocrine disorders, and hormone replacement therapy. The company also provides insulin pens, growth hormone pens, and injection needles. In addition, it offers smart solutions for diabetes treatment, such as smart insulin pens and Dose Check, an insulin dose guidance application. The company has a collaboration agreement with UNICEF to tackle childhood obesity; and with Valo Health, Inc. to discover and develop novel drug programmes for cardiometabolic space. Novo Nordisk A/S was founded in 1923 and is headquartered in Bagsvaerd, Denmark.